CBD seems to be the wonder drug of the century for many, but there are still those who think more studies need to be done. In a review to be published in the Mayo Clinic Proceedings, researchers have suggested that there might need to be many more human trials before health care providers will be able to definitively say if it is effective for people.
Brent Bauer MD works as a director of research at the Mayo Clinic Integrative Medicine programme, he said “There are many intriguing findings in pre-clinical studies that suggest CBD and hemp oil have anti-inflammatory effects and may be helpful with improving sleep and anxiety, but trials in humans are still limited, so it is too early to be definitive about efficacy and safety.”
Dr. Bauer was pointing these things out for the safety of patients. He has found that there has been a growing number of reports of patients with liver injuries who are using CBD and hemp oil products for their conditions. Making sure that patient interest is number one for many doctors like Dr. Bauer. That’s a large part of the reason the NHS has been so reluctant to prescribe medical cannabis to patients.
Dr. Bauer went on to say, “Careful selection of a health care product is crucial, and though these products do not have Food and Drug Administration approval for therapeutic use, patients continue to ask for them and use them. Physicians need to become better informed about these products, and it’s important that human trials examine issues of efficacy and safety.”
More education required
While these products could be potentially beneficial for many patients with chronic pain and addiction management, the report concludes, it is important for health care professionals to learn as much as humanly possible for their patients to have the best options. At the current time, there are not enough regulations on CBD, and there are little to no rigorous safety studies being conducted on CBD oils. With more human trials it is hoped that this will prompt more of these.
In the US, similar trials were conducted by the British firm GW Pharmaceuticals, and it convinced the U.S. Food and Drug Administration to approve Epidiolex, a CBD drug made by GW, for sale on the US market.